AgeX Therapeutics (NYSE:AGE) Stock Price Down 0.9%

Posted by on Jun 14th, 2023

AgeX Therapeutics, Inc. (NYSE:AGE – Get Rating) shares traded down 0.9% during mid-day trading on Tuesday . The stock traded as low as $0.66 and last traded at $0.67. 6,026 shares traded hands during trading, a decline of 71% from the average session volume of 20,886 shares. The stock had previously closed at $0.68.

AgeX Therapeutics Trading Down 0.9 %

The stock has a fifty day moving average price of $0.58 and a 200-day moving average price of $0.61. The firm has a market capitalization of $25.58 million, a price-to-earnings ratio of -2.32 and a beta of 1.50.

AgeX Therapeutics (NYSE:AGE – Get Rating) last posted its earnings results on Friday, March 31st. The company reported ($0.07) earnings per share for the quarter. The business had revenue of $0.01 million during the quarter.

Institutional Investors Weigh In On AgeX Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Susquehanna International Group LLP acquired a new position in shares of AgeX Therapeutics during the fourth quarter worth $29,000. Creative Planning boosted its position in AgeX Therapeutics by 38.2% during the second quarter. Creative Planning now owns 72,360 shares of the company’s stock valued at $42,000 after acquiring an additional 20,000 shares during the last quarter. Finally, Sigma Planning Corp boosted its position in shares of AgeX Therapeutics by 15.2% during the 4th quarter. Sigma Planning Corp now owns 134,977 shares of the company’s stock worth $74,000 after purchasing an additional 17,777 shares in the last quarter. 12.51% of the stock is currently owned by institutional investors.

AgeX Therapeutics Company Profile

(Get Rating)

AgeX Therapeutics, Inc operates as a biotechnology company, which engages in the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. Its product pipeline includes AGEX-VASC1, AGEX-BAT1, and AGEX-iTR1547. The company was founded by Michael D. West in 2017 and is headquartered in Alameda, CA.

Featured Stories

Receive News & Ratings for AgeX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgeX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.